What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
M.U., D.S
Immunol Today (1999) 20:36775
Discontinuing Glucagon-Like Peptide-1 Receptor Agonists and Body Habitus: A Systematic Review and Meta-Analysis
Key Benefits: Drastically minimizes the look of eyelid creases & crepiness Helps improve visible firmness & reduce the look of sagging around the eye area Smooths eyelid texture to help prevent eye makeup from creasing Featured Ingredients: Neuropeptides: Protein-like messenger molecules reduce the look of stubborn expression lines and deep creases by supporting visible skin renewal for a relaxed, smooth appearance
